Table 2

 Baseline characteristics of study patients (intent-to-treat population)

ETN (n = 159)ETN+MTX (n = 155)
DAS28, Disease Activity Score-28 joint count; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; ETN, etanercept; HAQ, Health Assessment Questionnaire; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; RA, rheumatoid arthritis; VAS, Visual Analogue Scale.
Mean age, years5354
Ethnic origin, n (%)
    White158 (99.4)153 (98.7)
    Black0 (0)2 (1.3)
    Asian1 (0.6)0 (0)
Sex, n (%)
    Female126 (79.2)119 (76.8)
    Male33 (20.8)36 (23.2)
Mean time since primary diagnosis,years10.09.8
Rheumatoid factor positive, %70.969.5
Prior corticosteroid use, n (%)78 (49.1)86 (55.5)
Prior NSAID use, n (%)116 (73)123 (79.4)
Mean ESR, mm/h33.236.7
Mean duration of morning stiffness,min235261
Mean DAS28 (4)6.26.3
Median MTX dose, mg/week1515
Mean no of prior DMARDs2.22.3
Mean no of total joint replacements15.716.8
Mean general health VAS (0–100)62.359.4
Mean pain VAS (0–100)62.763.3
Global assessment of RA activity VAS (0–10)6.66.6
Mean HAQ (0–3)1.61.7
Mean no of swollen joints11.211.9
Mean no of tender joints14.614.7